Medpace shares rose 15.9% this morning to a price of $217.1. The stock is still trading within range of its average target price of $210.33, and over the last 52 weeks, it has recorded a 41.2% performance. Analysts have given the mid-cap Biotechnology stock target prices ranging from $199.0 to $217.0 dollars per share, with an average rating of hold.
The stock has an average amount of shares sold short at 7.6%, and a short ratio of 4.26. Since 44.85% of the company's shares are owned by insiders, we can infer that there is a degree of alignment between management and shareholder interests. Finally, we also note that a significant number of institutional investors are invested in the stock, with 81.5% of Medpace's shares being owned by this investor type.
Institutions Invested in Medpace
| Date Reported | Holder | Percentage | Shares | Value |
|---|---|---|---|---|
| 2022-12-31 | Blackrock Inc. | 10% | 3,163,131 | $686,717,931 |
| 2022-12-31 | Vanguard Group, Inc. (The) | 9% | 2,696,146 | $585,335,164 |
| 2022-12-31 | Wasatch Advisors Inc | 5% | 1,637,818 | $355,571,422 |
| 2022-12-31 | Fuller & Thaler Asset Management Inc. | 3% | 938,198 | $203,683,435 |
| 2022-12-31 | State Street Corporation | 3% | 829,820 | $180,154,496 |
| 2022-12-31 | Dimensional Fund Advisors LP | 2% | 591,321 | $128,376,198 |
| 2022-12-31 | Invesco Ltd. | 2% | 591,745 | $128,468,249 |
| 2022-12-31 | Geode Capital Management, LLC | 2% | 585,815 | $127,180,842 |
| 2023-03-31 | Boston Trust Walden Corporation | 2% | 562,635 | $122,148,448 |
| 2022-12-31 | Millennium Management Llc | 1% | 450,938 | $97,898,952 |
